Wright Medical Group (WMGI) : Analyst Rating Update

Wright Medical Group (WMGI) has an average broker rating of 1.47, which is interpreted as a Strong Buy, as rated by 17 equity analysts. Nonetheless, 12 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Wright Medical Group (WMGI) : The consensus price target for Wright Medical Group (WMGI) is $26.31 for the short term with a standard deviation of $3.97. The most optimist securities analyst among the 13 who monitor the stock believes that the stock can reach $33, however, the pessimist price target for the company is $22.

Wright Medical Group (NASDAQ:WMGI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.35 and $18.26 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.90, notching a gain of 2.72% for the day. The total traded volume was 1,330,763 . The stock had closed at $18.40 on the previous day.

Also, Guggenheim Securities initiates coverage on Wright Medical Group (NASDAQ:WMGI) The brokerage firm has issued a Buy rating on the shares. The rating by the firm was issued on June 9, 2016. The company shares have dropped -26.84% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $26.13 and the one year low was seen on Feb 10, 2016. The 50-Day Moving Average price is $18.37 and the 200 Day Moving Average price is recorded at $18.75.

Wright Medical Group, Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology, Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients lifestyles. The Company operates through three segments: U.S., International and BioMimetic. The Companys business includes products that are used in foot and ankle repair, upper extremity products and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Companys products include extremity hardware, foot and ankle hardware, upper extremity hardware and biologics.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.